about
Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancerModified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers.Early concurrent chemoradiotherapy with prolonged oral etoposide and cisplatin for limited-stage small-cell lung cancer.Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.Sunitinib in metastatic renal cell carcinoma patients with brain metastases.Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective studySunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.The role of PET/CT in detection of gastric cancer recurrence.Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in KoreaRecursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy.Impact of multimodality approach for patients with leptomeningeal metastases from solid tumorsClinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors.The Changes in MGMT Promoter Methylation Status in Initial and Recurrent GlioblastomasAnalysis of the BRAF(V600E) Mutation in Central Nervous System Tumors.Definitive Radiotherapy versus Postoperative Radiotherapy for Tonsil Cancer.Influence of Comorbidities on the Efficacy of Radiotherapy with or without Chemotherapy in Elderly Stage III Non-small Cell Lung Cancer PatientsAnalysis of Fifty Hotspot Mutations of Lung Squamous Cell Carcinoma in Never-smokers.Role of chemotherapy on brain metastasis.Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial.Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy.Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI.The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer.Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.Preradiation chemotherapy with ACNU-CDDP in patients with newly diagnosed glioblastoma: a retrospective analysis.Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma.Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor.Definitive radiotherapy with or without chemotherapy for T3-4N0 squamous cell carcinoma of the maxillary sinus and nasal cavity.Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.Primary intracranial germ cell tumor originating from septum pellucidum that mimics central neurocytoma.VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib.
P50
Q27852049-5C8E04DB-1F6E-4F88-AF19-2C98DB5A2C31Q33281956-503A6DCB-6CD3-410C-B159-BF08B630D68CQ33304691-D537B3BC-412A-40D6-8E93-A756C86D5F87Q33337970-5C6D75FD-471F-4D83-972A-3EBA372093A9Q33357243-FF8B19DC-3C7C-4F1E-B029-CA7EDDFA0D56Q33358915-F5C67DCC-98A3-4762-911C-E983A06AF584Q33365502-25ACDCAF-F155-4509-94E7-686C78046CCEQ33385435-3F9D6561-BF6A-4DAA-BEFD-85EA3ECB80FCQ33391978-0DDD0408-1B1F-4ED2-94E4-3865D3CD9496Q33394065-A57F5304-39EE-42FC-8D3E-5C0592F1812DQ33396613-DDE3E30C-5633-4235-A803-00D9924757AEQ33413458-0A506A80-4908-40B1-99C5-2DD2C1BEF172Q33416602-E14EEFD1-FA8A-4808-809D-01B7EA6C900CQ33519196-02B03004-6132-4A68-B01E-11366A8593A5Q34029965-366902FA-570A-4C93-B1FF-124E9BB5C543Q34167362-6BA73E6E-4FDF-4EFE-A02B-EDD90824CCF0Q36310665-A8ABF625-395D-47B3-A73E-8BA6F46C3F12Q36525778-D0F7ED6A-6DE4-4E24-B7F8-CB066C1188F8Q36536973-46862CC0-7F11-4C94-AC01-948AAEA64428Q36536988-8D053993-59AF-488D-84F3-9FE2337CFF84Q37622296-8DA044E3-C1E3-4F40-80E8-3FFAA33A8E0FQ37975020-B26FE80F-1FB3-4E87-A9AB-6A414A9E6AD2Q38498924-3014EF5E-157D-4439-9753-D137297C82B9Q39820287-84EEF7C9-21EE-4E07-80E0-A27A19DCECF6Q40331396-F6A541EA-49FF-4BB2-B530-31C8C8201E67Q42718762-94D98E5C-7C9C-4ACB-9A7D-8C8C7377C4DAQ42974538-339B58FD-59D1-452B-9B08-7D5693477B31Q43953167-B305FC10-420B-445E-817A-DBD2D628C328Q44012358-0060D30D-91B3-459F-9079-0DB44C7B0624Q45093247-7B15A3D2-8828-4501-BC09-FB55E1CA3348Q46038645-C860474F-FE75-429F-A446-78E9480C718CQ46064283-34F7D606-B487-4098-B6AD-541BB777DAEFQ46146247-90EEBF24-1A0C-4799-8F6E-8CE591EC9DA4Q46212157-6168450B-64F0-46D4-963F-5CCA243E311FQ46883617-16635E16-A1E9-4CE4-B495-EAECD78F3FD9Q47702103-875E490B-5372-4544-9A4D-BB7A1F1FC4A5Q48293044-797C2350-7C5B-4D56-BF60-77DF616150FBQ48412951-50FAD476-BC08-4829-AC2E-986E98E32239Q48430558-5387C886-6963-4EA6-A9B0-7BCECFFE1DC1Q51429594-9C984419-48E7-41B5-BDED-A3D67B3F6150
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Se-Hoon Lee
@ast
Se-Hoon Lee
@en
Se-Hoon Lee
@es
Se-Hoon Lee
@nl
Se-Hoon Lee
@sl
type
label
Se-Hoon Lee
@ast
Se-Hoon Lee
@en
Se-Hoon Lee
@es
Se-Hoon Lee
@nl
Se-Hoon Lee
@sl
prefLabel
Se-Hoon Lee
@ast
Se-Hoon Lee
@en
Se-Hoon Lee
@es
Se-Hoon Lee
@nl
Se-Hoon Lee
@sl
P1153
P106
P1153
16637829200
35313481500
39262058200
P31
P496
0000-0002-9219-3350